Skip to main content
SpringerLink
Log in

Advanced Breast Cancer: Treatment with Docetaxel/Epirubicin

  • Chapter
Methods of Cancer Diagnosis, Therapy and Prognosis

Part of the book series: Methods of Cancer Diagnosis, Therapy and Prognosis ((HAYAT,volume 1))

  • 2076 Accesses

Metastatic breast cancer (MBC) remains a fatal disease despite the great amount of research performed in recent years and the progress achieved. The median survival of patients with MBC is ∼ 18–24 months after the initial diagnosis of metastases (Dickson et al., 2005). Hence, the principal goals of treatment are palliation of symptoms and prolongation of survival while maintaining or improving the quality of life. Many drugs have been approved for the treatment of MBC and among them the taxanes and anthracyclines represent the two major chemotherapy classes commonly used in daily practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 309.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 399.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • A'Hern, R.P., Smith, I.E., and Ebbs, S.R. 1993. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.Br. J. Cancer 67: 801–805

    PubMed  Google Scholar 

  • Bastholt, L., Dalmark, M., Gjedde, S.B., Pfeiffer, P., Pedersen, D., Sandberg, E., Kjaer, M., Mouridsen, H.T., Rose, C., Nielsen, O.S., Jakobsen, P., and Bentzen, S.M. 1996. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.J. Clin. Oncol. 14: 1146–1155

    PubMed  CAS  Google Scholar 

  • Bonneterre, J., Dieras, V. , Tubiana-Hulin, M., Bougnoux, P., Bonneterre, M.E., Delozier, T., Mayer, F., Culine, S., Dohoulou, N., and Bendahmane, B. 2004. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epi-rubicin and cyclophosphamide in metastatic breast cancer.B r. J. Cancer 91: 1466–1471

    CAS  Google Scholar 

  • Brufman, G., Colajori, E., Ghilezan, N., Lassus, M., Martoni, A., Perevodchikova, N., Tosello, C., Viaro, D., and Zielinski, C. 1997. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann. Oncol. 8: 155–162

    Article  PubMed  CAS  Google Scholar 

  • Ceruti, M., Tagini, V., Recalenda, V. , Arpicco, S., Cattel, L., Airoldi, M., and Bumma, C. 1999. Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.Farmaco 54: 733–739

    Article  PubMed  CAS  Google Scholar 

  • Chan, S., Friedrichs, K., Noel, D., Pinter, T., VanBelle, S., Vorobiof, D., Duarte, R., Gil, G.M., Bodrogi, I., Murray, E., Yelle, L., von Minckwitz, G., Korec, S., Simmonds, P., Buzzi, F., Gonzalez, M.R., Richardson, G., Walpole, E., Ronzoni, M., Murawsky, M., Alakl, M., Riva, A., and Crown, J. 1999. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.J. Clin. Oncol. 17: 2341–2354

    PubMed  CAS  Google Scholar 

  • Conte, P.F., Baldini, E., Gennari, A., Michelotti, A., Salvadori, B., Tibaldi, C., Danesi, R., Innocenti, F., Gentile, A., Dell'Anna, R., Biadi, O., Mariani, M., and DelTacca, M. 1997. Dose-finding study and pharmacokinetics of epiru-bicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.J. Clin. Oncol. 15: 2510–2517

    PubMed  CAS  Google Scholar 

  • Cortes, J.E., and Pazdur, R. 1995. Docetaxel.J. Clin. Oncol. 13: 2643–2655

    PubMed  CAS  Google Scholar 

  • Crivellari, D., Pagani, O., Veronesi, A., Lombardi, D., Nole, F., Thurlimann, B., Hess, D., Borner, M., Bauer, J., Martinelli, G., Graffeo, R., Sessa, C., and Goldhirsch, A. 2001. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.Ann. Oncol. 12: 353–356

    Article  PubMed  CAS  Google Scholar 

  • Crown, J. 2001. Docetaxel: overview of an active drug for breast cancer.Oncologist 6: 1–4

    Article  PubMed  CAS  Google Scholar 

  • Dickson, R.B., Pestell, R.G., and Lippman, M.E. 2005. Cancer of the Breast. in: Principles and Practice of Oncology, DeVita, V.T., Hellman, S., and Rosenberg, S.A. Eds Lippincott Williams & Wilkins, Philadelphia, 7th Edition: 1399–1487

    Google Scholar 

  • Ellis, M.J., Hayes, D.F., and Lippman, M.E. 2000. Treatment of metastatic breast cancer. in: Diseases of the Breast, Lippman, M.E., Morrow, M., and Osborne, C.K., Eds Lippincott, Williams & Willkins, Philadelphia: 749–797

    Google Scholar 

  • Fabi, A., Papaldo, P., Pino, M.S., Ferretti, G., Carlini, P. , Pacetti, U., Di Cosimo, S., Nardoni, C., Giannarelli, D., Sacchi, I., and Cognetti, F. 2004. Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.Anticancer Res. 24: 1963–1967

    PubMed  CAS  Google Scholar 

  • Feld, R., Wierzbicki, R., Walde, P.L., Shepherd, F.A., Evans, W.K., Gupta, S., Shannon, P., and Lassus, M. 1992. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.J. Clin. Oncol. 10: 297–303

    PubMed  CAS  Google Scholar 

  • Ganzina, F. 1983. 4̃-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.Cancer Treat. Rev. 10: 1–22

    Article  PubMed  CAS  Google Scholar 

  • Gehl, J., Boesgaard, M., Paaske, T., Vittrup, J.B., and Dombernowsky, P. 1996. Combined doxo-rubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.Ann. Oncol. 7: 687–693

    PubMed  CAS  Google Scholar 

  • Gueritte-Voegelein, F., Guenard, D., Lavelle, F., Le Goff, M.T., Mangatal, L., and Potier, P. 1991. Relationships between the structure of taxol analogues and their antimitotic activity.J. Med. Chem. 34: 992–998

    Article  PubMed  CAS  Google Scholar 

  • Hainsworth, J.D., Yardley, D.A., Spigel, D.R., Meluch, A.A., Rinaldi, D., Schnell, F.M., and Greco, F.A. 2006. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial.Cancer Invest. 24: 469–473

    Article  PubMed  CAS  Google Scholar 

  • Holmes, F.A., Walters, R.S., Theriault, R.L., Forman, A.D., Newton, L.K., Raber, M.N., Buzdar, A.U., Frye, D.K., and Hortobagyi, G.N. 1991. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.J. Natl. Cancer Inst. 83: 1797–1805

    Article  PubMed  CAS  Google Scholar 

  • Kouroussis, C., Xydakis, E., Potamianou, A., Giannakakis, T., Kakolyris, S., Agelaki, S., Sara, E., Malamos, N., Alexopoulos, A., Mavroudis, D., Samonis, G., Papadouris, S., Georgoulias, V. , and Panagos, G. 1999. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).Ann. Oncol. 10: 547–552

    Article  PubMed  CAS  Google Scholar 

  • Launchbury, A.P., and Habboubi, N. 1993. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.Cancer Treat. Rev. 19: 197–228

    Article  PubMed  CAS  Google Scholar 

  • Mavroudis, D., Alexopoulos, A., Ziras, N., Malamos, N., Kouroussis, C., Kakolyris, S., Agelaki, S., Kalbakis, K., Tsavaris, N., Potamianou, A., Rigatos, G., and Georgoulias, V. 2000. Frontline treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.Ann. Oncol. 11: 1249–1254

    Article  PubMed  CAS  Google Scholar 

  • Milla-Santos, A., Milla, L., Rallo, L., and Solano, V. 2001. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.Am. J. Clin. Oncol. 24: 138–142

    Article  PubMed  CAS  Google Scholar 

  • Morales, S., Lorenzo, A., Ramos, M., Ballesteros, P., Mendez, M., Almanza, C., Castellanos, J., Moreno-Nogueira, J.A., Casal, J., Lizon, J., Oltra, A., Frau, A., Machengs, I., Galan, A., Belon, J., and Llorca, C. 2004. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.Cancer Chemother. Pharmacol. 53: 75–81

    PubMed  Google Scholar 

  • Nabholtz, J.M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., and Winograd, B. 1996. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.J. Clin. Oncol. 14: 1858–1867

    PubMed  CAS  Google Scholar 

  • Nabholtz, J.M., Senn, H.J., Bezwoda, W.R., Melnychuk, D., Deschenes, L., Douma, J., Vandenberg, T.A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., Drbal, J., Molino, A., Nortier, J.W., Richel, D.J., Nagykalnai, T., Siedlecki, P., Wilking, N., Genot, J.Y., Hupperets, P.S., Pannuti, F., Skarlos, D., Tomiak, E.M., Murawsky, M., Alakl, M., and Aapro, M. 1999. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthra-cycline-containing chemotherapy. 304 Study Group.J. Clin. Oncol. 17: 1413–1424

    PubMed  CAS  Google Scholar 

  • Nabholtz, J.M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., Pienkowski, T., Zaluski, J., Pinter, T., Krzakowski, M., Vorobiof, D., Leonard, R., Kennedy, I., Azli, N., Murawsky, M., Riva, A., and Pouillart, P. 2003. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.J. Clin. Oncol. 21: 968–975

    Article  PubMed  CAS  Google Scholar 

  • Pagani, O., Sessa, C., Martinelli, G., Crivellari, D., Buonadonna, A., Thurlimann, B., Hess, D., Borner, M., Bauer, J., Zampino, G., Zimatore, M., Graffeo, R., Riva, A., and Goldhirsch, A. 1999. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.Ann. Oncol. 10: 539–545

    Article  PubMed  CAS  Google Scholar 

  • Pagani, O., Sessa, C., Nole, F., Crivellari, D., Lombardi, D., Thurlimann, B., Hess, D., Borner, M., Bauer, J., Martinelli, G., Graffeo, R., Zucchetti, M., D'Incalci, M., and Goldhirsch, A. 2000. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.Ann. Oncol. 11: 985–991

    Article  PubMed  CAS  Google Scholar 

  • Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J.G., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Van Vreckem, A., Sylvester, R., Awada, A., Wildiers, J., and Piccart, M. 2000. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.J. Clin. Oncol. 18: 724–733

    PubMed  CAS  Google Scholar 

  • Ravdin, P.M. 1997. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.Semin. Oncol. 24: 10–17

    Google Scholar 

  • Rowinsky, E.K. 1997. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.Ann. Rev. Med. 48: 353–374

    Article  PubMed  CAS  Google Scholar 

  • Salminen, E., Korpela, J., Varpula, M., Asola, R., Varjo, P., Pyrhonen, S., Mali, P., Hinkka, S., and Ekholm, E. 2002. Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.Anticancer Drugs 13: 925–929

    Article  PubMed  CAS  Google Scholar 

  • Salminen, E., Syvanen, K., Korpela, J., Varpula, M., Antila, K., Varjo, P., and Ekholm, E. 2003. Docetaxel with epirubicin—investigations on cardiac safety.Anticancer Drugs 14: 73–77

    Article  PubMed  CAS  Google Scholar 

  • Sledge, G.W., Neuberg, D., Bernardo, P., Ingle, J.N., Martino, S., Rowinsky, E.K., and Wood, W.C. 2003. Phase III trial of doxorubicin, paclit-axel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for meta-static breast cancer: an intergroup trial (E1193).J. Clin. Oncol. 21: 588–592

    Article  PubMed  Google Scholar 

  • Valero, V. , Jones, S.E., Vo n Hoff, D.D., Booser, D.J., Mennel, R.G., Ravdin, P.M., Holmes, F.A., Rahman, Z., Schottstaedt, M.W., Erban, J.K., Esparza-Guerra, L., Earhart, R.H., Hortobagyi, G.N., and Burris, H.A. III. 1998. A phase II study of docetaxel in patients with paclitaxel-resist-ant metastatic breast cancer.J. Clin. Oncol. 16: 3362–3368

    PubMed  CAS  Google Scholar 

  • Venturini, M., Michelotti, A., Papaldo, P., Del Mastro, L., Bergaglio, M., Lionetto, R., Lunardi, G., Sguotti, C., Frevola, L., Donati, S., Rosso, R., and Cognetti, F. 2001. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.Ann. Oncol. 12: 1097–1106

    Article  PubMed  CAS  Google Scholar 

  • Verweij, J., Clavel, M., and Chevalier, B. 1994. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.Ann. Oncol. 5: 495–505

    PubMed  CAS  Google Scholar 

  • Viens, P., Roche, H., Kerbrat, P., Fumoleau, P., Guastalla, J.P., and Delozier, T. 2001. Epirubicin— docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.Am. J. Clin. Oncol. 24: 328–335

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 711 10, Heraklion, Crete, Greece

    A. G. Pallis, V. Georgoulias & V. Mavroudis

Authors
  1. A. G. Pallis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Mavroudis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, Kean University, Union, NJ, USA

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science + Business Media B.V.

About this chapter

Cite this chapter

Pallis, A.G., Georgoulias, V., Mavroudis, V. (2008). Advanced Breast Cancer: Treatment with Docetaxel/Epirubicin. In: Hayat, M.A. (eds) Methods of Cancer Diagnosis, Therapy and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8369-3_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-8369-3_27

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-8368-6

  • Online ISBN: 978-1-4020-8369-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation